Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PEPG by emailGet an email when PEPG pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PEPG, unsubscribe in one click. Privacy
📣 What PEPG Says Is Next
first half of 2027 · “Read the full release here. o Results from the 12.5 mg/kg cohort of FREEDOM2 are expected in the first half of 2027.”
Company press release, Aug 6, 2026 · SEC filing
second half of 2026 · “PepGen expects to report data from this cohort in the second half of 2026, with data from the 12.5 mg/kg cohort anticipated in 2027. o PepGen has currently enrolled 13 patients in the open label extension (OLE) at 5 mg/kg, including 6 patients from FREEDOM2, with no patient discontinuations. o The Company has received regulatory clearance to initiate the FREEDOM2 trial in South Korea, Australia, and New Zealand.”
Company press release, May 12, 2026 · SEC filing
second half of this year · “"Enrollment in the 10 mg/kg cohort is now complete and we remain on track to report data in the second half of this year.”
Company press release, May 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PEPG picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PEPG and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.